{"links":{"feed":"https://www.erudio.com/reports/arion-nct03777813/feed.json","html":"https://www.erudio.com/reports/arion-nct03777813","json":"https://www.erudio.com/reports/arion-nct03777813.json","markdown":"https://www.erudio.com/reports/arion-nct03777813.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"arion-nct03777813"}},"request":"https://www.erudio.com/contact?report=arion-nct03777813"},"offer":{"cited_clinicians":3,"cited_commentary_sources":6,"verified_hcp_statements":14,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":6},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"arion-nct03777813"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=arion-nct03777813","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/arion-nct03777813","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 14 verified statements · 5 from 3 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T00:15:03.555628Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: cPFS (centrally reviewed cPFS)"},{"claim_count":8,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":5,"title":"Secondary endpoint: Overall survival (OS)"},{"claim_count":3,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":3,"title":"Secondary endpoint: Adverse Events"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":0,"title":"Secondary endpoint: Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting)"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":3,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":3,"title":"Younger-patient survival signal and patient-selection research"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":2,"title":"Other negative immunotherapy–chemoradiotherapy studies as interpretive context"},{"claim_count":1,"coverage":"discussed","id":"A3","source_count":1,"title":"Radiation's immunological interpretation"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"Cross-setting integration of radiotherapy and systemic treatment"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":1,"cited_clinicians":3,"cited_clinicians_by_role":{"physician, Gastroenterology":1,"physician, Radiation oncology":2},"cited_physicians":3,"cited_sources":6,"claims_by_expression_type":{"comparison":1,"interpretation":6,"opinion":2,"question":1,"restatement":4},"claims_by_kind":{"source_observation":14},"clinician_statements":5,"evidence_units":9,"findings":5,"people_cited":7,"people_identity_verified":6,"people_total":7,"screened_sources":16,"verified_claims":14},"findings_index":[{"cited_clinicians":2,"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":4},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"ARION: why speakers see no significant PFS or OS benefit from adding durvalumab","title_holders":{"cited_claim_ids":["claim-b7196b30e504002eadfc","claim-3d2833dfab120b65e974","claim-1ed7cba980f9d27859a8","claim-2392b3afcf4a76f40288","claim-7ad58844160e8ebb9138"],"clinicians":false,"holders":5,"speakers":5,"view":"reading"},"evidence_line":"7 statements from 5 speakers in 5 sources, 1 of them a podcast or video","holder_line":"5 of the 5 named speakers in this finding hold this view"},{"cited_clinicians":1,"id":"F2","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":1},"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"ARION safety: most speakers see no new signal, but most flag severe toxicity","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-94e1031492f6180524ac","claim-b3a1f2e89646007341af"],"clause":"most flag severe toxicity","holders":2},"cited_claim_ids":["claim-b5b8f2c5593cbf4cdab7","claim-94e1031492f6180524ac"],"clinicians":false,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"3 statements from 3 speakers in 3 sources","holder_line":"2 of the 3 named speakers in this finding hold this view; 2 of the 3 hold its caveat, “most flag severe toxicity”"},{"cited_clinicians":1,"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Under-65 OS: speakers flag a signal, but a clinician calls it exploratory only","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-ae9840761b164cb92f4f"],"clause":"a clinician calls it exploratory only","holders":1},"cited_claim_ids":["claim-b5b8f2c5593cbf4cdab7","claim-ae9840761b164cb92f4f","claim-b3a1f2e89646007341af"],"clinicians":false,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"5 statements from 3 speakers in 3 sources","holder_line":"3 of the 3 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician calls it exploratory only”"},{"cited_clinicians":1,"id":"F4","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"ARION: a clinician views radiation as mostly immunosuppressive","title_holders":{"cited_claim_ids":["claim-db66e0ef5e3d51e7444e"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":0,"id":"F5","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":0},"limitations":1,"links":{"context":0,"support":1},"ma_question":false,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"RT and systemic therapy: a speaker asks about integration across settings","title_holders":{"cited_claim_ids":["claim-bc2e9dcd775fc08aac5a"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"basis":"From finding F3 (5 statements from 3 speakers in 3 sources)","cited_claim_ids":["claim-b7196b30e504002eadfc","claim-b5b8f2c5593cbf4cdab7","claim-b75aca1bdc7fe514dd34","claim-ae9840761b164cb92f4f","claim-b3a1f2e89646007341af"],"finding_ids":["F3"],"question":"What evidence do clinicians say is needed to determine whether adding durvalumab to definitive chemoradiotherapy improves overall survival in patients younger than 65 with localised unresectable oesophageal cancer, beyond ARION’s exploratory findings?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"X accounts and an interview speaker see no demonstrated efficacy benefit"},{"id":"section-2","level":2,"title":"One X account reports no safety signal alongside substantial severe toxicity"},{"id":"section-3","level":2,"title":"X accounts flag a younger-patient signal; one limits it to hypothesis generation"},{"id":"section-4","level":2,"title":"One X account offers an immunosuppression interpretation of radiation"},{"id":"section-5","level":2,"title":"Beyond the trial population"},{"id":"section-6","level":3,"title":"One LinkedIn author asks whether radiotherapy can be better integrated with systemic treatment"},{"id":"section-7","level":2,"title":"Scope and coverage of the reviewed discussion"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: cPFS (centrally reviewed cPFS)"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4}],"id":"T2","label":"Secondary endpoint: Overall survival (OS)"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2}],"id":"T3","label":"Secondary endpoint: Adverse Events"},{"findings":[],"id":"T4","label":"Secondary endpoint: Quality of Life OES18, used for patients with oesophageal cancer always complemented by the QLQ-C30 measuring 5 functional scales (physical, everyday activity, cognitive, emotional and social) and 3 symptoms scales (fatigue, pain, nausea and vomiting)"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":1}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":1}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T00:15:03.555628Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T01:06:12Z","record_hash":"809746b0d3683e8676f92ec7f1d7c1679a1779233c9a8933d270c71b2d23b16f","release_hash":"ada8382fe422a80c6bc75f4d17ce6455489f8b43fc1937f21bd495ba8a778a11","report_id":"erudio-nct03777813","run_id":"27281524-6c38-46c7-957d-89553dc1ed63","schema_version":"5.0","slug":"arion-nct03777813","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited read ARION as negative because reported outcomes did not improve, with one radiation oncologist qualifying that reading by the small, predominantly squamous cohort. That clinician reports frequent severe treatment-related toxicity but no safety signal, and regards the younger-patient survival observation as hypothesis-generating. Differences between numerical accounts remain unexplained. The sources place the phase II results at ESMO 2026.","examples":[],"meta_description":"16 sources screened · 14 verified statements (5 from clinicians verified by NPI or staff page) from 6 sources · 5 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T01:06:12Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":16},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 46 sources about other trials or topics are not included; discussion that uses 4 names the trial shares with other things, without the trial's condition or setting, may be missing.","The sources reviewed for this edition are a limited set of public discussions, not a representative sample of treating clinicians; repeated circulation does not establish independent agreement.","Discussion without the trial's names or identifiers, or using different wording or transcription variants, may be missing.","No protocol was listed in the trial's ClinicalTrials.gov record, and no results publication for this exact trial was identified. The report describes attributed accounts rather than independently reconciled efficacy and safety results.","A speaker's and Martinez another speaker's hazard-ratio summaries differ without an explanation in their statements, so the estimates are not combined.","The younger-patient survival observation remains a trend or exploratory signal, and the expected value of ancillary studies is prospective."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":1,"youtube":0},"by_evidence_role":{"commentary":6},"count":6,"evidence_window":{"end":"2026-11-14","start":"2026-09-30"},"retrieval_snapshot":"2026-11-20T23:16:00.411199Z","timeline":[{"count":1,"week":"2026-W40"},{"count":4,"week":"2026-W43"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT03777813:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03777813:context","quote_policy":"short_quote_link_out"},{"id":"openfda:8baba4ea-2855-42fa-9bd9-5a7548d4cec3:20260831","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7510976788987244544","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7519437247864242176","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102432534395306414:7a9f6256-9c22-449a-a219-2d895ac28e69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105272977118154822:b0ef51ee-22ca-45b8-a2f3-285b5808297e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110607787776745536:625008de-2bc6-4231-857f-9831793f24da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111952609083105626:ddd91044-d736-498e-899c-eedf5eb23a48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112902368220287215:f730ae81-aa09-487b-9d1c-337436f579c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113387641013936310:0ba7dc2e-d331-4f4e-a77f-e179aa5d4245","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113405836659687651:ae7fbff3-62de-4804-938d-40c8ded47345","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113651745951801447:9f581790-7730-45b5-990c-413d7ef234c5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113652798235517432:d9fa6161-b4ab-422a-a70a-d0ef16653a8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114392335119167582:5ed3bbe0-3b8b-48e7-a2ed-fc5fd5ec474b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117205750564966645:780ca1ab-b680-4888-bcce-115d2fb1c697","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2121737439836504517:29271cf0-8939-4c50-9725-105556a10dc7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2121737439836504517","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:UPZh2UPiV8U","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":12,"x_video":1,"youtube":1},"by_evidence_role":{"commentary":16},"count":16,"evidence_window":{"end":"2026-11-14","start":"2026-09-22"},"retrieval_snapshot":"2026-11-20T23:50:46.332862Z","timeline":[{"count":1,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":2,"week":"2026-W42"},{"count":7,"week":"2026-W43"},{"count":1,"week":"2026-W45"},{"count":2,"week":"2026-W46"}],"undated_sources":1},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":4,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":3,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":[{"abstracts":1,"label":"ESMO Congress 2026","slug":"esmo26","sources":9}],"drugs":[{"brand_names":["Imfinzi"],"label":"durvalumab","slug":"durvalumab"},{"reason":"Unmapped registry intervention: imrt 50 gy + folfox4 simplified (oxaliplatin, leucovorin, 5-fu)","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Esophageal cancer","slug":"esophageal-cancer"},{"reason":"Unmapped registry condition: Unresectable Malignant Neoplasm","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ARION","aliases":["ARION","Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer","Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial"],"brief_title":"Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Esophagus Cancer","Unresectable Malignant Neoplasm"],"display_condition":"localised unresectable esophageal cancer","display_interventions":[["durvalumab"]],"enrollment":{"count":112,"type":"ACTUAL"},"interventions":[{"name":"Durvalumab","synonyms":["IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)"],"type":"DRUG"},{"name":"IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"COMBINATION_PRODUCT"}],"nct_id":"NCT03777813","official_title":"Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial","other_names":[{"kind":"also","name":"PRODIGE 67"}],"overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2024-05-24","type":"ACTUAL"},"primary_endpoints":[{"description":"defined by a blinded independent centralized revue of progression free survival. cPFS is defined as the time from randomization until progression or death; patients alive and without documented progression at last follow-up news have PFS censored at this date or at initiation of new anticancer treatment (if applicable). Progression will be defined with central external reviewing of TDM per RECIST v1.1","measure":"cPFS (centrally reviewed cPFS)","timeFrame":"12-months cPFS"}],"registered_date":{"date":"2018-12-17","type":"ACTUAL"},"registry_last_updated":"2025-11-18","registry_url":"https://clinicaltrials.gov/study/NCT03777813","short_name":"ARION","short_name_basis":"registry_acronym","sponsor":"UNICANCER","start_date":{"date":"2018-12-05","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"UC-110/1719 -PRODIGE 67-UCGI33","type":"sponsor_study_id"},{"id":"2018-000708-40","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}